Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report

This study reports the positive effect of osteoanabolic treatment with once-daily recombinant human parathyroid hormone 1 –34 (rhPTH 1–34, teriparatide) in a 20-year-old DMD boy suffering from multiple vertebral fractures causing back pain. Bone formation and resorption markers (osteocalcin and C-telopeptide of type I collagen, respectively), as expected, increased within 6 months and intensity of back pain early decreased, with no pain reported after 6 months at visual analog scale. Over a 18-month period of treatment with teriparatide, bone mineral density and quality of life, assessed by the 36-item short-form questionnaire, considerably improved and no side effects were reported. Further studies on larg e cohorts are warranted to test the efficacy of this promising treatment for DMD related osteoporosis.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research